Detection and minimally invasive treatment of early squamous lung cancer

Abstract

Non-small cell lung cancer (NSCLC) is the most common cause of cancer deaths worldwide. The majority of patents presenting with NSCLC have advanced disease, which precludes curative treatment. Early detection and treatment might result in the identification of more patients with early central lung cancer and improve survival. In addition, the study of early lung cancer improves understanding of lung carcinogenesis and might also reveal new treatment targets for advanced lung cancer. Bronchoscopic investigation of the central airways can reveal both early central lung cancer in situ (stage 0) and other preinvasive lesions such as dysplasia. In the current review we discuss the detection of early squamous lung cancer, the natural history of preinvasive lesions and whether biomarkers can be used to predict progression to cancer. Finally we will review the staging and management of preinvasive lung cancer lesions and the different therapeutic modalities that are available.

Diagnosis and Treatment of Three Cases of Bronchial Carcinoma In Situ

“…Such an approach is applied routinely by different authors, but the most prominent center is T. Sutedjas's in Amsterdam. 6 Other authors speculate with the place of CIS placing it together with moderate and high grade dysplasia in the group of preinvasive lesions. 7 There is an opinion that this group of changes can progress spontaneously and regress also.…”

A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non–Small Cell Carcinoma In Situ or Non–Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study

“…The trial (NCI-2010-02114) was carried out at RPCI between August 2004 and April 2013. HPPH was used at a fixed, previously determined systemic dose of 4 mg/m 27, 13–15 . The study followed a conventional 3+3 dose escalation scheme, designed to determine the maximally tolerated light dose (MTD) 16 .…”

“…A substantial proportion of these patients also have significant cardiovascular and pulmonary comorbidities, which preclude surgical resection. Therefore advanced bronchoscopic techniques like photodynamic therapy (PDT), electrocautery, argon plasma coagulation (APC), cryotherapy and laser are usually chosen to treat CIS/MIC 2 .…”

Modern approaches to the diagnosis of precancerous pathology and early lung cancer

“…Основным недостатком AFI является ее невысокая специфичность. Выявление значительного количества ложнопозитивных очагов слизистой оболочки бронхов приводит к большому количеству неэффективных гистологических исследований [37].…”